Fernando Jorge-Rodriguez

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

Discontinuation of disease-modifying therapies in patients with multiple sclerosis: A retrospective case-control study.

Discontinuation of disease-modifying therapies in patients with multiple sclerosis: A retrospective case-control study.

Journal: Multiple sclerosis and related disorders
Published: March 21, 2026

New serum soluble factors predicting inflammatory and non-inflammatory disability worsening in multiple sclerosis.

New serum soluble factors predicting inflammatory and non-inflammatory disability worsening in multiple sclerosis.

Journal: Frontiers in immunology
Published: October 21, 2025

Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis.

Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis.

Journal: International journal of molecular sciences
Published: June 24, 2025

Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosis.

Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosis.

Journal: Frontiers in immunology
Published: June 17, 2025

Corrigendum: Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.

Corrigendum: Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.

Journal: Frontiers in immunology
Published: November 26, 2024

Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients.

Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients.

Journal: International journal of molecular sciences
Published: November 19, 2024

Progression independent of relapse activity can be predicted by passively acquired tapping speed through a smartphone for 1 month: A prospective study.

Progression independent of relapse activity can be predicted by passively acquired tapping speed through a smartphone for 1 month: A prospective study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: September 09, 2024

Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.

Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.

Journal: Frontiers in immunology
Published: August 14, 2024

Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.

Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.

Journal: Frontiers in immunology
Published: June 25, 2024

Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy Adults.

Establishing Normal Serum Values of Neurofilament Light Chains and Glial Fibrillary Acidic Protein Considering the Effects of Age and Other Demographic Factors in Healthy Adults.

Journal: International journal of molecular sciences
Published: June 21, 2024

COVID-19 vaccines are not associated with axonal injury in patients with multiple sclerosis.

COVID-19 vaccines are not associated with axonal injury in patients with multiple sclerosis.

Journal: Frontiers in immunology
Published: May 27, 2024

Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.

Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.

Journal: CNS drugs
Published: February 01, 2024
Showing 1-12 of 32

Last Updated: 09/26/2026